(Reuters) – British drugmaker AstraZeneca said on Tuesday its diabetes drug Farxiga was successful in reducing the risk of death by heart attack or the worsening of a type of heart failure in a late-stage clinical trial.
Farxiga met the main goal of the DAPA-HF trial which tested the medicine, in addition to the standard treatment, in patients whose heart cannot pump enough blood. The trial included patients with and without type-2 diabetes.
The results are welcome news for AstraZeneca after U.S. regulators declined to approved Farxiga for use as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels.
“The result will also reinforce Farxiga’s utility in diabetes at a time when oral GLP-1 might enter the market,” they added, referring to a rival group of drugs.
GLP-1 drugs, on the other hand, imitate an intestinal hormone that stimulates the production of insulin. Danish insulin producer Novo Nordisk has already grabbed a chunk of the diabetes market with its GLP-1 drug Ozempic here.
Farxiga, one of AstraZeneca’s top 10 drugs by sales, is already approved for use in type-2 diabetes, the more common form of the condition.
AstraZeneca shares were up 1.6% at 7,397 pence as of 0827 GMT.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Patrick Graham and Mark Potter